REGN7508 for Blood Clots in Cancer Patients

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Recruiting Phase 3 Interventional Study
Venous Thromboembolism (VTE)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
1,600 (estimated)
Sponsor
Regeneron Pharmaceuticals · Industry
Who this trial is looking for

This trial is looking for adults with or without cancer who have blood clots in veins or lungs. Participants will take a study drug called REGN7508 to see how well it works compared to another treatment.

Are You a Good Fit for This Trial?
Rules you out Acute leukemiaMyelodysplastic syndrome

You may be able to join if

  • I am 18 years or older.
  • I have a confirmed diagnosis of cancer or blood clots.
  • I have a good performance status (ECOG 0 to 2).
  • I have newly diagnosed DVT or VTE within the last 5 days.
  • I have already been on blood thinner therapy for a required period.

You may not be able to join if

  • I have a high risk of bleeding in my head or brain.
  • I have a bleeding disorder.
  • I have a life expectancy of less than 6 months.
  • I have had a recent symptomatic pulmonary embolism.
  • I have acute leukemia or myelodysplastic syndrome.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \[DVT\]) that block blood flow (Part 1) or focused on participants with cancer who develop blood clots in certain veins (DVT) or the lung…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: 1. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 at the time of screening and day 1 prior to first dose of study intervention 2. In Part 1 participants with cancer and Part 2 participants: Histologically confirmed diagnosis of malignant solid …
Contacts

Clinical Trials Administrator

844-734-6643

clinicaltrials@regeneron.com

CONTACT